Dual Immunotherapy IO Treatment and Sequencing Decisions for Melanoma
Source: Cancer Network, December 2024
Panelists discuss how dual immunotherapy for melanoma, including combinations like nivolumab plus ipilimumab or nivolumab plus relatlimab, requires careful consideration of sequencing decisions based on factors such as tumor burden, patient health status, and potential toxicity profiles.
